Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Centessa Pharmaceuticals (CNTA) Depreciation & Amortization (CF): 2019-2024

Historic Depreciation & Amortization (CF) for Centessa Pharmaceuticals (CNTA) over the last 5 years, with Dec 2024 value amounting to $942,000.

  • Centessa Pharmaceuticals' Depreciation & Amortization (CF) rose 0.42% to $237,000 in Q3 2025 from the same period last year, while for Sep 2025 it was $910,000, marking a year-over-year decrease of 5.01%. This contributed to the annual value of $942,000 for FY2024, which is 16.30% up from last year.
  • Centessa Pharmaceuticals' Depreciation & Amortization (CF) amounted to $942,000 in FY2024, which was up 16.30% from $810,000 recorded in FY2023.
  • Centessa Pharmaceuticals' Depreciation & Amortization (CF)'s 5-year high stood at $942,000 during FY2024, with a 5-year trough of $34,000 in FY2021.
  • For the 3-year period, Centessa Pharmaceuticals' Depreciation & Amortization (CF) averaged around $627,667, with its median value being $810,000 (2023).
  • Data for Centessa Pharmaceuticals' Depreciation & Amortization (CF) shows a peak YoY skyrocketed of 518.32% (in 2023) over the last 5 years.
  • Yearly analysis of 4 years shows Centessa Pharmaceuticals' Depreciation & Amortization (CF) stood at $34,000 in 2021, then surged by 285.29% to $131,000 in 2022, then soared by 518.32% to $810,000 in 2023, then increased by 16.30% to $942,000 in 2024.